Aytu Biopharma Inc (AYTU) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket
 
Aytu Biopharma Inc  (NASDAQ: AYTU)
 

Aytu Biopharma Inc Growth Comparisons

Select each growth Category to receive further Information





AYTU Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q1 MRQ) -34.86 % 12.24 % 9.19 % 10.9 %
Q / Q Revenue Growth (Q1 MRQ) -20.69 % -2.93 % -3.28 % 8.32 %
Y / Y Revenue Growth (for 12 months ending Q1 TTM) -18.72 % 9.25 % 7.98 % %
Sequential Revenue Growth (for 12 months ending Q1 TTM) -10.03 % 2.69 % 2.03 % 2.61 %
Revenue 5 Year Average Growth 18.96 % 7.41 % 8.65 % 10.59 %


AYTU's Growth Comparisons in III. Quarter 2026




Aytu Biopharma Inc's Revenue were slashed by -34.86% in the third quarter 2026 from the same quarter a year ago, to $ 12 millions, while sales in theMajor Pharmaceutical Preparations industry grew by 12.24%, and underperformed the 9.19% Revenue growth in the Healthcare sector. Comparing the third quarter, sales Aytu Biopharma Inc was trailing overall market not just Major Pharmaceutical Preparations industry.

Comparing company's Revenue to the second quarter results, sales were lower by -20.69% . On the annual basis, average annual sales growth for Aytu Biopharma Inc is 18.96%, while S & P 500's including only Businesses with the third quarter 2026 results, average yearly sales growth is 10.59% over the past five years.

AYTU Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
RX Segment
-
-18.16 %
RX E X X U A Portfolio
-
894.61 %
RX ADHD Portfolio
-
-31.2 %
RX The Pediatric Portfolio
-
-45.47 %
Total
-34.86 %
-20.69 %


Growth Rates of AYTU's Income in the third quarter 2026


AYTU Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q1 MRQ) - -8.69 % 5.13 % 97.6 %
Sequential Operating Income Change (Q1 MRQ) - -4.52 % 0.89 % 48.13 %
Y / Y Operating Income Growth (Q1 TTM) - 30.63 % 30.7 % 40.67 %
Sequential Operating Income Growth (Q1 TTM) - -2.27 % 4.82 % 20.86 %
Operating Income 5 Year Avg. Change - 14.39 % 10.39 % 18.76 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q1 MRQ) - -34.78 % -25.81 % 90.69 %
Sequential Income from Cont. Ops. Change (Q1 MRQ) - -2.61 % -66.16 % 27.07 %
Y / Y Income from Cont. Ops. Change (Q1 TTM) - 6.3 % 2.68 % 57.33 %
Sequential Income from Cont. Ops. Change (Q1 TTM) - -10.02 % -5.02 % 18.65 %
Income from Cont. Ops. 5 Year Avg. Change - -0.55 % 0.17 % -28.52 %

AYTU Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q1 MRQ) - -35.13 % -26.29 % 90.69 %
Q / Q Net Income Growth (Q1 MRQ) - 2.8 % -0.86 % 27.07 %
Y / Y Net Income Change (Q1 TTM) - 5.21 % 15.47 % 57.33 %
Sequential Net Income Change (Q1 TTM) - -10.17 % -6.74 % 18.65 %
Net Income 5 Year Avg. Growth - 14.55 % 9.21 % 22.96 %

AYTU's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q1 MRQ) - -40.16 % -25.81 % 90.69 %
Sequential EPS from Cont. Ops. Change (Q1 MRQ) - -7.73 % -66.16 % 27.07 %
Y / Y EPS from Cont. Ops. Change (Q1 TTM) - - - -
Sequential EPS from Cont. Ops. Change (Q1 TTM) - - - 4.88 %
EPS from Cont. Ops. 5 Year Avg. Growth - -10.79 % 0.17 % -28.52 %



AYTU EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q1 MRQ) - -40.49 % -26.29 % -28.52 %
Q / Q EPS Net Growth (Q1 MRQ) - -2.61 % -0.86 % 27.07 %
Y / Y EPS Net Change (for 12 months ending Q1 TTM) - - - 7.62 %
Sequential EPS Net Change (for 12 months ending Q1 TTM) - - 0.15 % 4.93 %
EPS Net 5 Year Avg. Change - 14.55 % 9.21 % 22.96 %



Aytu Biopharma Inc reported bottom-line of $ -0.53 in the third quarter, compare to $ 0.21 in the same quarter a year ago. Major Pharmaceutical Preparations industry fell by -40.49%, while Healthcare sector decreased by -26.29%, and overall market improved by 90.69%.

Comparing the company's EPS to the second quarter results, income per share were lower by -20.69% . On the annual basis, average annual income per share growth for Aytu Biopharma Inc is 18.96%, while S & P 500's including only Businesses with the third quarter 2026 financial reports, average yearly income per share growth is 22.96% over the past five years.

AYTU Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q1 MRQ) - 25.53 % 48.48 % 48.62 %
Sequential Free Cash Flow Change (Q1 MRQ) - -42.35 % -46.96 % 34.18 %
Y / Y Free Cash Flow Change (Q1 TTM) - 11.91 % 18.61 % 60.27 %
Sequential Free Cash Flow Change (Q1 TTM) - 3.24 % 5.39 % 15.75 %
Free Cash Flow 5 Year Avg. Change - 1.86 % 0.92 % 8.28 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q1 MRQ) - - - 339.02 %
Sequential Net Cash Flow Change (Q1 MRQ) - - - 216.68 %
Y / Y Net Cash Flow Change (Q1 TTM) - - - 209.43 %
Sequential Net Cash Flow Change (Q1 TTM) - - - 152.64 %
Net Cash Flow 5 Year Avg. Change -21.64 % 29.88 % 6.46 % 1.06 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q1 MRQ) - 11.25 % 8.23 % 120.03 %
Sequential Capital Expenditures Change (Q1 MRQ) - -25.6 % -22.09 % 36.87 %
Y / Y Capital Expenditures Change (Q1 TTM) 1337.91 % 16.65 % 7.86 % 109.38 %
Sequential Capital Expenditures Change (Q1 TTM) -2.22 % 2.92 % 1.6 % 23.05 %
Capital Expenditures 5 Year Avg. Change -11.21 % 7.84 % 8.61 % 14.73 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 







Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.